HC Wainwright Comments on Inozyme Pharma Q1 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Inozyme Pharma in a research report issued to clients and investors on Friday, January 10th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Inozyme Pharma's current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma's Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05.

A number of other equities analysts have also weighed in on the company. Raymond James started coverage on Inozyme Pharma in a research note on Thursday, December 12th. They set an "outperform" rating and a $26.00 target price on the stock. Wells Fargo & Company lowered their price objective on Inozyme Pharma from $14.00 to $11.00 and set an "overweight" rating on the stock in a research report on Monday. Wedbush restated an "outperform" rating and issued a $12.00 price target on shares of Inozyme Pharma in a research note on Friday. Piper Sandler lowered their price target on shares of Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $23.00 price objective on shares of Inozyme Pharma in a report on Wednesday, November 6th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $18.33.

Inozyme Pharma Stock Performance

INZY stock traded down $0.28 during mid-day trading on Monday, hitting $1.72. 1,516,904 shares of the company were exchanged, compared to its average volume of 918,272. Inozyme Pharma has a 1-year low of $1.61 and a 1-year high of $7.80. The stock has a market capitalization of $110.49 million, a PE ratio of -1.10 and a beta of 1.35. The business has a 50 day simple moving average of $3.02 and a 200-day simple moving average of $4.38. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C bought a new stake in Inozyme Pharma during the second quarter worth $52,000. Virtu Financial LLC bought a new stake in shares of Inozyme Pharma during the 3rd quarter worth $64,000. Meeder Asset Management Inc. acquired a new stake in Inozyme Pharma in the second quarter valued at about $68,000. SG Americas Securities LLC bought a new position in Inozyme Pharma in the third quarter valued at about $81,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Inozyme Pharma during the second quarter worth about $84,000. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.